Precocious puberty is usually defined as the onset of secondary sexual characteristics prior to age 7 1/2-8 in girls and prior to age 9 in boys. Although sex steroids cause growth acceleration and tall stature in the short term, the potential for a significant loss of ultimate adult height is a central concern in all children with pathologic forms of early puberty. Unlike central precocious puberty (CPP), which refers to early activation of the hypothalamic-pituitary-gonadal axis, peripheral precocious puberty (PPP) arises from abnormal sex steroid exposure from other sources. These may be endogenous or exogenous, congenital, or acquired. The clinical presentation will depend on the underlying process and on the class of sex steroids (estrogens or androgens) involved. Although many different causes of PPP exist, the most common are congenital adrenal hyperplasia (CAH), familial male-limited precocious puberty (FMPP), and McCune Albright syndrome (MAS). The pathophysiology and clinical characteristics of each of these will be described. A variety of factors are known to influence growth in these disorders. The impact of primary and adjuvant treatment on growth and ultimate height in children with these conditions will be discussed. Data regarding the long-term outcome of established clinical management as well as preliminary findings from investigational approaches will also be summarized.
|Original language||English (US)|
|Title of host publication||Handbook of Growth and Growth Monitoring in Health and Disease|
|Publisher||Springer New York|
|Number of pages||14|
|State||Published - Jan 1 2012|
ASJC Scopus subject areas